699 related articles for article (PubMed ID: 1358484)
1. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
Riedel M; Günther T; von zur Mühlen A; Brabant G
Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
[TBL] [Abstract][Full Text] [Related]
2. Regulation of pulsatile growth hormone secretion by fasting in normal subjects and patients with acromegaly.
Ho PJ; Friberg RD; Barkan AL
J Clin Endocrinol Metab; 1992 Sep; 75(3):812-9. PubMed ID: 1517371
[TBL] [Abstract][Full Text] [Related]
3. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
[TBL] [Abstract][Full Text] [Related]
4. Neonatal treatment with monosodium glutamate: effects of prolonged growth hormone (GH)-releasing hormone deficiency on pulsatile GH secretion and growth in female rats.
Maiter D; Underwood LE; Martin JB; Koenig JI
Endocrinology; 1991 Feb; 128(2):1100-6. PubMed ID: 1989848
[TBL] [Abstract][Full Text] [Related]
5. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.
Moller DE; Moses AC; Jones K; Thorner MO; Vance ML
J Clin Endocrinol Metab; 1989 Feb; 68(2):499-504. PubMed ID: 2493033
[TBL] [Abstract][Full Text] [Related]
6. The interaction of growth hormone releasing hormone and somatostatin in the generation of a GH pulse in man.
Hindmarsh PC; Brain CE; Robinson IC; Matthews DR; Brook CG
Clin Endocrinol (Oxf); 1991 Oct; 35(4):353-60. PubMed ID: 1684314
[TBL] [Abstract][Full Text] [Related]
7. The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin(1-14)(SS) in growth hormone (GH) pulse generation: studies in normal and post cranial irradiated individuals.
Achermann JC; Hindmarsh PC; Robinson IC; Matthews DR; Brook CG
Clin Endocrinol (Oxf); 1999 Nov; 51(5):575-85. PubMed ID: 10594518
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous octreotide treatment of a growth hormone-releasing hormone-secreting bronchial carcinoid: superiority of continuous versus intermittent administration to control hormonal secretion.
Lefebvre S; De Paepe L; Abs R; Rahier J; Selvais P; Maiter D
Eur J Endocrinol; 1995 Sep; 133(3):320-4. PubMed ID: 7581949
[TBL] [Abstract][Full Text] [Related]
9. Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion.
Gelato MC; Oldfield E; Loriaux DL; Merriam GR
J Clin Endocrinol Metab; 1990 Sep; 71(3):585-90. PubMed ID: 2118536
[TBL] [Abstract][Full Text] [Related]
10. The influence of octreotide treatment on pulsatile growth hormone release in acromegaly.
Roelfsema F; de Boer H; Frölich M
Clin Endocrinol (Oxf); 1990 Aug; 33(2):297-306. PubMed ID: 2225485
[TBL] [Abstract][Full Text] [Related]
11. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
[TBL] [Abstract][Full Text] [Related]
12. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men.
Iranmanesh A; South S; Liem AY; Clemmons D; Thorner MO; Weltman A; Veldhuis JD
Eur J Endocrinol; 1998 Jul; 139(1):59-71. PubMed ID: 9703380
[TBL] [Abstract][Full Text] [Related]
13. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
[TBL] [Abstract][Full Text] [Related]
14. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin--a clinical research center study.
Jaffe CA; Turgeon DK; Friberg RD; Watkins PB; Barkan AL
J Clin Endocrinol Metab; 1995 Nov; 80(11):3321-6. PubMed ID: 7593445
[TBL] [Abstract][Full Text] [Related]
15. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
16. Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone-releasing hormone.
Bondanelli M; Ambrosio MR; Margutti A; Franceschetti P; Zatelli MC; degli Uberti EC
Neuroendocrinology; 2003 Jun; 77(6):380-7. PubMed ID: 12845224
[TBL] [Abstract][Full Text] [Related]
17. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy.
Ho KY; Weissberger AJ
Clin Endocrinol (Oxf); 1994 Jul; 41(1):75-83. PubMed ID: 8050134
[TBL] [Abstract][Full Text] [Related]
18. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.
Huhn WC; Hartman ML; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1993 May; 76(5):1202-8. PubMed ID: 8496311
[TBL] [Abstract][Full Text] [Related]
19. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
[TBL] [Abstract][Full Text] [Related]
20. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Gouwy S; Stockman W; Weekers F; Schetz M; Lauwers P; Bouillon R; Bowers CY
Clin Endocrinol (Oxf); 1997 Nov; 47(5):599-612. PubMed ID: 9425400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
